Abstract
Purpose of review: To update readers on recent literature regarding treatment of coagulopathy for patients with life-threatening bleeding, highlighting emerging therapeutic options, controversial topics, and ongoing clinical trials. Recent findings: Massive transfusion protocols featuring immediate availability of blood products and multidisciplinary communication reduce mortality and conserve resources. There is a growing consensus that immediate administration of plasma and platelet units in a 1:1: 1 ratio with red cell units reduces early mortality. Lyophilized and recombinant blood product components may have advantages over traditional blood products in certain clinical circumstances. Summary: Massive transfusion protocols standardize treatment of the coagulopathy of massive bleeding, leading to rapid restoration of hemostasis and decrease in early mortality.
Original language | English (US) |
---|---|
Pages (from-to) | 263-268 |
Number of pages | 6 |
Journal | Current Opinion in Anaesthesiology |
Volume | 23 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2010 |
Keywords
- Acute coagulopathy of trauma
- Damage control resuscitation
- Massive transfusion protocol
- Prothrombin complex concentrate
- Recombinant factor VIIa
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine